Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
This study has been completed.
Study NCT00043706   Information provided by Genzyme
First Received: August 12, 2002   Last Updated: June 19, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Systemic Sclerosis
Scleroderma
Additional conditions recognized in this trial
Scleroderma, Diffuse
Scleroderma, Systemic
Sclerosis
More general conditions related to this trial
Connective Tissue Diseases
Pathologic Processes
Skin Diseases
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
Immunoglobulins
Mitogens
More general drug interventions related to this trial
Immunologic Factors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Genzyme
Cambridge Antibody Technology


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services